Ultragenyx Pharmaceutical Inc. (RARE) Form 8-K — Oct 7, 2026
Ultragenyx Pharmaceutical agreed on October 6, 2026 to sell its Rare Pediatric Disease Priority Review Voucher for $210 million in cash at closing. The PRV was awarded by the FDA on August 19, 2026 following approval of GENGLYCOS (DTX401) for glycogen storage disease type Ia.
Key figures
- Gross Proceeds
- 210000000
- Prv award date
- 2026-08-19
- Buyer premium note
- Buyer name not disclosed
- Nih royalty percent
- 20
AI analysis
Red flags2 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.